Q Biomed Inc Quick Ratio (QBIO) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Q Biomed inc   (QBIO)

Q Biomed Inc 's Quick Ratio

QBIO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2023, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 636 other companies have achieved higher Quick Ratio than Q Biomed Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 5474 to 5825.

Explain Quick Ratio?
How much Cash & cash equivalents QBIO´s has?
What are QBIO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QBIO Quick Ratio (Feb 28 2023)
Q1		 (Nov 30 2022)
Q4		 (Aug 31 2022)
Q3		 (May 31 2022)
Q2		 (Feb 28 2022)
Q1
Y / Y Current Liabilities Change 55.55 % 48.01 % 114.91 % 153.98 % 140.43 %
Y / Y Cash & cash equivalent Change -83.11 % -85.47 % -8.85 % -90.65 % -68.47 %
Quick Ratio MRQ 0 0.01 0.02 0 0.02
QBIO's Total Ranking # 5825 # 5474 # 4792 # 4816 # 5100
Seq. Current Liabilities Change 21.8 % 5.18 % 2.27 % 18.73 % 15.9 %
Seq. Cash & cash equivalent Change -53.63 % -63.74 % 407.33 % -80.2 % -60.12 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 637
Healthcare Sector # 1260
Overall Market # 5825


Quick Ratio Statistics
High Average Low
7.34 1.02 0
(Feb 28 2018)   (Feb 28 2023)




Financial Statements
Q Biomed Inc 's Current Liabilities $ 10 Millions Visit QBIO's Balance sheet
Q Biomed Inc 's Cash & cash equivalent $ 0 Millions Visit QBIO's Balance sheet
Source of QBIO's Sales Visit QBIO's Sales by Geography


Cumulative Q Biomed Inc 's Quick Ratio

QBIO's Quick Ratio for the trailling 12 Months

QBIO Quick Ratio

 (Feb 28 2023)
12 Months		 (Nov 30 2022)
12 Months		 (Aug 31 2022)
12 Months		 (May 31 2022)
12 Months		 (Feb 28 2022)
12 Months
Y / Y Current Liabilities TTM Growth 80.78 % 102.43 % 149.32 % 161.31 % 85.45 %
Y / Y Cash & cash equivalent TTM Growth -74.19 % -71.15 % -70.67 % -87 % -83.29 %
Quick Ratio TTM 0.01 0.01 0.02 0.03 0.05
Total Ranking TTM # 4673 # 4200 # 4450 # 4320 # 4662
Seq. Current Liabilities TTM Growth 11.87 % 9.71 % 17.96 % 24.86 % 25.27 %
Seq. Cash & cash equivalent TTM Growth -32.38 % -45.5 % -2.03 % -28.53 % -24.41 %

Quick ratio ranking by company, industry and sector >> Back to QBIO Financial Strength Comparisons >> Go to Compare QBIO Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the growth in Current Liabilities in the Q1 2023 to $9.91 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Q Biomed Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 600 other companies have achieved higher Quick Ratio than Q Biomed Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4200 to 4673.

Explain Quick Ratio?
How much Cash & cash equivalents QBIO´s has?
What are QBIO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 601
Healthcare Sector # 1196
Within the Market # 4673


trailing twelve months Quick Ratio Statistics
High Average Low
4.65 0.94 0.01
(Nov 30 2018)   (Feb 28 2023)




Companies with similar Quick Ratio in the quarter ending Feb 28 2023, within Major Pharmaceutical Preparations Industry Quick RatioFeb 28 2023 MRQ Cash & cash equivalentFeb 28 2023 MRQ Current Liabilities
Theralink Technologies Inc 0.00 $ 0.228  Millions$ 53.422  Millions
Provectus Biopharmaceuticals Inc 0.00 $ 0.034  Millions$ 8.660  Millions
Rapid Therapeutic Science Laboratories Inc 0.00 $ 0.018  Millions$ 4.463  Millions
Novaccess Global Inc 0.00 $ 0.022  Millions$ 5.830  Millions
Kaya Holdings Inc 0.00 $ 0.030  Millions$ 9.690  Millions
Adhera Therapeutics Inc 0.00 $ 0.069  Millions$ 23.197  Millions
Q Biomed inc 0.00 $ 0.023  Millions$ 9.906  Millions
REGENEREX PHARMA, INC. 0.00 $ 0.001  Millions$ 0.519  Millions
Actavia Life Sciences Inc 0.00 $ 0.002  Millions$ 1.923  Millions
Rebus Holdings Inc 0.00 $ 0.005  Millions$ 5.662  Millions
Kamada Ltd 0.00 $ 0.027  Millions$ 49.649  Millions

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.